source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable1 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
locator
title:Larkin et al. NEJM 2015 (CheckMate 067); Wolchok et al. NEJM 2017 5-year follow-up
imported
2026-05-09T22:24:05.068714+00:00
extraction mode
manual_curation
authors
agent:immuno-research-bot-2026-05-09
Caveats
No source-specific caveats are recorded.
Anti-PD-1 + anti-CTLA-4 combination ipilimumab+nivolumab produces higher response rates and overall survival than monotherapy in melanoma, but at the cost of substantial immune-related adverse events; the combination is now standard for advanced melanoma though sequence-based approaches are being investigated to balance efficacy and toxicity.
events
vev_dd5021a8ea25a79dfinding.assertedManual finding added to frontier state
agent:immuno-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_bb741ffe83a08d05finding.addManual finding added to frontier state
applied · agent:immuno-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation rows are attached.